ADORA2A and neoplasm: Preclinical evidence showed that while targeting individual A2AR- or A2BR-axis each positively impacted antitumor immunity and generally delayed tumor progression (60–62), we found that combined anti-CD73, A2AR- and A2BR-axis blockade markedly improved anti-tumor immunity with tumor regression (32).